SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+55.66%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$296M
AUM Growth
+$296M
(+33%)
Cap. Flow
+$55.4M
Cap. Flow
% of AUM
18.69%
Top 10 Holdings %
Top 10 Hldgs %
46.59%
Holding
90
New
21
Increased
29
Reduced
18
Closed
11
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$24M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$11.5M |
| 3 |
Krystal Biotech
KRYS
|
$9.97M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
$4.81M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$4.67M |
Top Sells
| 1 |
BLU
BELLUS Health Inc.
BLU
|
$7.2M |
| 2 |
Nuvalent
NUVL
|
$7.02M |
| 3 |
Pharvaris
PHVS
|
$5.44M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$4.11M |
| 5 |
Immatics
IMTX
|
$2.9M |
Sector Composition
| 1 | Healthcare | 99.91% |
| 2 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Alkermes
ALKS
$4.78B
| $1.25M | 0.39% | +40,000 | New | +$1.25M |
|
52
Voyager Therapeutics
VYGR
$186M
| $1.15M | 0.35% | +100,000 | New | +$1.15M |
|
53
Viridian Therapeutics
VRDN
$1.5B
| $1.07M | 0.33% | 45,000 +8,619 | +24% | +$205K |
|
54
Rezolute
RZLT
$619M
| $989K | 0.31% | +499,544 | New | +$989K |
|
55
Karyopharm Therapeutics
KPTI
$61.7M
| $929K | 0.29% | 518,985 -1,022,441 | -66% | -$1.83M |
|
|
ALLK
56
DELISTED
Allakos
ALLK
| $872K | 0.27% | 200,000 -11,010 | -5% | -$48K |
|
57
BioMarin Pharmaceuticals
BMRN
$11.2B
| $867K | 0.27% | +10,000 | New | +$867K |
|
58
BridgeBio Pharma
BBIO
$9.89B
| $860K | 0.27% | 50,000 +10,000 | +25% | +$172K |
|
|
PNT
59
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $849K | 0.26% | 93,700 -104,777 | -53% | -$949K |
|
60
Ventyx Biosciences
VTYX
$171M
| $820K | 0.25% | 25,000 -45,000 | -64% | -$1.48M |
|
61
Protagonist Therapeutics
PTGX
$3.67B
| $691K | 0.21% | 25,000 -80,486 | -76% | -$2.22M |
|
62
Jasper Therapeutics
JSPR
$45.5M
| $685K | 0.21% | 500,000 | – | – |
|
63
Aligos Therapeutics
ALGS
$73.3M
| $614K | 0.19% | 631,887 | – | – |
|
64
Biohaven
BHVN
$1.63B
| $478K | 0.15% | +20,000 | New | +$478K |
|
65
Syndax Pharmaceuticals
SNDX
$1.41B
| $419K | 0.13% | +20,000 | New | +$419K |
|
66
Compugen
CGEN
$132M
| $376K | 0.12% | 330,188 | – | – |
|
|
67
Immatics
IMTX
$619M
| $354K | 0.11% | 30,715 -251,717 | -89% | -$2.9M |
|
68
Celldex Therapeutics
CLDX
$1.47B
| $339K | 0.11% | 10,000 -74,651 | -88% | -$2.53M |
|
69
Clene
CLNN
$53.1M
| $220K | 0.07% | +250,000 | New | +$220K |
|
70
Monte Rosa Therapeutics
GLUE
$296M
| $213K | 0.07% | 31,156 | – | – |
|
|
ELOX
71
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
| $210K | 0.07% | 54,075 | – | – |
|
|
PVLA
72
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $159K | 0.05% | +961,338 | New | +$159K |
|
73
Evogene
EVGN
$10.9M
| $107K | 0.03% | +100,000 | New | +$107K |
|
74
Glaukos
GKOS
$5.5B
| $71.2K | 0.02% | +1,000 | New | +$71.2K |
|
|
VRAY
75
DELISTED
ViewRay, Inc.
VRAY
| $35.2K | 0.01% | 100,000 -2,693,748 | -96% | -$949K |
|